Gary Jacob on Muck Rack

Gary Jacob

Verified
As seen in: The Times, Manawatū Standard, Stuff.co.nz, The Marlborough Express, The Nelson Mail, The Southland Times, The Sunday Times, The Timaru Herald, The Courier-Journal (Louisville, KY), ADVFN, The Press (New Zealand) and
Sports reporter, The Times. Views my own. Previous life analysing breathing patterns and the heart. bsky.app/profile/garyjacob.bsky.social
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gary

Contact Gary, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PSD Bank Rhein-Ruhr eG

|
By Gary Jacob 
| Sparda-Bank web.Börsenforum
* After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment. * Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.
Open in Who Shared View Duplicates (136) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Gary Jacob 
| Sparda-Bank web.Börsenforum
Nachrichtendetail 19.05.2025 13:00:07 - dpa-AFX: GNW-News: OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S.
Open in Who Shared View Duplicates (66) Issue with article?

PSD Bank Rhein-Ruhr eG

|
By Gary Jacob 
| Sparda-Bank web.Börsenforum
LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, today announces a clinical update and its interim results for the six months ended 30 September 2024.
Open in Who Shared View Duplicates (50) Issue with article?
See all 30 licensed articles (53 Total)

Actions

Share this page

Get in touch with Gary

Contact Gary, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified